Edition:
United Kingdom

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

7.43USD
4:45pm GMT
Change (% chg)

$-0.03 (-0.34%)
Prev Close
$7.45
Open
$7.48
Day's High
$7.50
Day's Low
$7.34
Volume
25,647
Avg. Vol
74,801
52-wk High
$9.22
52-wk Low
$3.76

Select another date:

Thu, Nov 2 2017

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON, Sept 7 GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy programme to boost its pipeline in oncology, one of four areas its has prioritised for research and development.

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​

Select another date: